Biotech firm Mabpharm tests Hong Kong listing

Jonathan Breen

March 11, 2019 10:00 am

unilab_Adobe_230x150 — Life scientists researching in laboratory. Female young scientist and her post doctoral supervisor microscoping in their working environment. Healthcare and biotechnology. | kasto - stock.adobe.com

China-based biotechnology firm Mabpharm is looking for the greenlight to list in Hong Kong, having filed a draft IPO prospectus with the city’s stock exchange.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOs Equity China International Capital Corp Hong Kong SAR Asia Greater China Northeast Asia Asia Pacific Emerging Markets SRI

JB

Jonathan Breen

Equities editor GlobalCapital Asia